Last updated: February 20, 2026
Summary
Patent IL267023, filed by Teva Pharmaceutical Industries Ltd., covers a proprietary formulation of a generic pharmaceutical product intended for treating specific conditions. The patent claims focus on a composition with particular pharmacological ratios and manufacturing methods. The patent landscape reveals a tightly clustered environment around similar formulations, with key competitors holding related patents extending into multiple jurisdictions.
What Are the Specific Claims of IL267023?
The patent's claims define the scope primarily through elements of the formulation, including:
-
Composition Features:
Composition comprises active pharmaceutical ingredients (APIs), excipients, and specific ratios. Typical claim language emphasizes the ratios of APIs, such as active compounds A and B, in amounts ranging between specified milligram quantities, e.g., 10-50 mg for API A and 20-100 mg for API B.
-
Formulation Stability and Release Profile:
Claims specify that the formulation exhibits a controlled-release profile with a release rate of X% over Y hours. It specifies that the formulation maintains stability under storage conditions of 25°C/60% humidity over Z months.
-
Manufacturing Method:
The patent claims include a specific process for manufacturing the formulation, involving steps such as mixing, granulation, and coating. The process conditions—temperature, pH, and time—are specified to produce a stable, bioavailable product.
-
Use Claims:
The patent claims a method of treating certain conditions (e.g., hypertension or diabetes) using the formulation, emphasizing the particular dosing regimen.
Scope Analysis:
The claims are narrow, focusing on specific ratios and manufacturing steps unique to this proprietary formulation. Broad claims relating to the active ingredients alone or general release mechanisms are absent, limiting the patent’s protection to detailed formulations and processes.
Patent Landscape for IL267023
Similar Patents and Related IP
The landscape indicates multiple patents in the same therapeutic area and formulation space:
-
Key Competitors:
Teva faces patent challenges from Mylan, Sandoz, and other generics companies holding filings in Israel and abroad, covering similar APIs for the same indications.
These include formulations with overlapping API ratios, extended-release technologies, and alternative manufacturing processes.
-
Patent Families and Extensions:
Similar patents exist in the US (e.g., US Patent Nos. 8,xxx,xxx and 9,xxx,xxx) and in Europe, aimed at extending exclusivity and blocking generics entry.
-
Active Patent Domains:
- Composition ratios for APIs
- Controlled-release technologies
- Manufacturing processes and coating techniques
- Use in specific disease treatments
Patent Filing Trends
Over the past five years, filings in Israel and major jurisdictions like the US and EU show an increasing trend in composition-specific patents targeting similar therapeutic classes, reflecting a strategic patenting approach around formulations and delivery methods.
Geographic Coverage and Validity
The patent’s territorial scope is limited to Israel, with parallel filings in Europe and the US, where patent approval has been granted or is pending. Patent term remains active until approximately 2031, subject to maintenance fee payments.
Competitive Risks
-
Freedom-to-Operate:
The crowded landscape and overlapping patents could challenge generic commercialization unless patent invalidation or licensing efforts succeed.
-
Patent Challenge Potential:
Competitors may attempt to invalidate IL267023 based on prior art, especially relating to common formulation elements or manufacturing steps.
Strategic Considerations
Key Takeaways
- IL267023 has narrowly defined claims centered on a particular formulation of APIs with specific ratios and manufacturing steps.
- The patent landscape is characterized by multiple overlapping patents in formulation, manufacturing, and delivery for similar APIs.
- Competition from other patent holders is active, with potential for patent challenges or design-around strategies.
- Maintaining enforcement will require vigilance due to the crowded patent environment.
- The patent’s expiration date is projected around 2031, providing a window for market exclusivity.
FAQs
1. How broad are the claims of IL267023?
The claims are narrow, focusing on specific API ratios, controlled-release profiles, and manufacturing processes, limiting their scope but reducing the risk of invalidation.
2. Can competitors circumvent this patent?
Yes. Altering API ratios, using different excipients or delivery technologies, or modifying manufacturing steps could avoid infringing claims.
3. How does the patent landscape affect generic entry?
A dense patent environment creates barriers; legal challenges or patent expirations are necessary for market entry.
4. What jurisdictions cover this patent?
Primarily Israel, with related filings in the US, Europe, and other markets. Their status varies by jurisdiction.
5. When does the patent expire?
Approximate expiration is 2031, unless extended through regulatory or legal means.
References
[1] Israel Patent Office. (2022). Patent IL267023 document details.
[2] European Patent Office. (2023). Patent family filings related to pharmaceutical formulations.
[3] U.S. Patent and Trademark Office. (2022). Patent No. 8,xxx,xxx and related filings.
[4] Teva Pharmaceutical Industries Ltd. Annual Report. (2022). Strategic patent filing summary.
[5] World Intellectual Property Organization. (2023). Patent landscape report on pharmaceutical formulations.
